Ceria nanoparticles ameliorate renal fibrosis by modulating the balance between oxidative phosphorylation and aerobic glycolysis
Authors:
Open Access
- 4 January 2022
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 20 (1) , 1-18
Abstract
Background and aims: Renal fibrosis is the common outcome in all progressive forms of chronic kidney disease. Unfortunately, the pathogenesis of renal fibrosis remains largely unexplored, among which metabolic reprogramming plays an extremely crucial role in the evolution of renal fibrosis. Ceria nanoparticles (CeNP-PEG) with strong ROS scavenging and anti-inflammatory activities have been applied for mitochondrial oxidative stress and inflammatory diseases. The present study aims to determine whether CeNP-PEG has therapeutic value for renal fibrosis. Methods: The unilateral ureteral obstructive fibrosis model was used to assess the therapeutic effects in vivo. Transforming growth factor beta1-induced epithelial-to-mesenchymal transition in HK-2 cells was used as the in vitro cell model. The seahorse bioscience X96 extracellular flux analyzer was used to measure the oxygen consumption rate and extracellular acidification rate. Results: In the present study, CeNP-PEG treatment significantly ameliorated renal fibrosis by increased E-cadherin protein expression, and decreased α-SMA, Vimentin and Fibronectin expression both in vitro and in vivo. Additionally, CeNP-PEG significantly reduced the ROS formation and improved the levels of mitochondrial ATP. The seahorse analyzer assay demonstrated that the extracellular acidification rate markedly decreased, whereas the oxygen consumption rate markedly increased, in the presence of CeNP-PEG. Furthermore, the mitochondrial membrane potential markedly enhanced, hexokinase 1 and hexokinase 2 expression significantly decreased after treatment with CeNP-PEG. Conclusions: CeNP-PEG can block the dysregulated metabolic status and exert protective function on renal fibrosis. This may provide another therapeutic option for renal fibrosis. GraphicalKeywords
Funding Information
- National Natural Science Foundation of China (81973385, 81801815)
- Youth Science Fund Project (31901002)
- Science and Technology Commission of Shanghai Municipality (20JC1419500)
- Scientific and Innovative Action Plan of Shanghai (20410713300)
This publication has 39 references indexed in Scilit:
- Mitochondrial Pathology and Glycolytic Shift during Proximal Tubule Atrophy after Ischemic AKIJournal of the American Society of Nephrology, 2016
- Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosisJournal of Hepatology, 2016
- Understanding the mechanisms of kidney fibrosisNature Reviews Nephrology, 2015
- Cerium oxide nanoparticles attenuate acute kidney injury induced by intra-abdominal infection in Sprague–Dawley ratsJournal of Nanobiotechnology, 2015
- Inhibition of MAP kinase/NF-kB mediated signaling and attenuation of lipopolysaccharide induced severe sepsis by cerium oxide nanoparticlesBiomaterials, 2015
- EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signalingCellular and Molecular Life Sciences, 2014
- Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis developmentNature Medicine, 2014
- Taming the chronic kidney disease epidemic: a global view of surveillance effortsKidney International, 2014
- Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosanBiomaterials, 2014
- Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathyCardiovascular Research, 2007